通心络胶囊联合瑞舒伐他汀治疗冠状动脉粥样硬化性心脏病临床观察  

Clinical Observation of Tongxinluo Capsules Combined with Rosuvastatin in the Treatment of Coronary Heart Disease

作　　者：陈坤伦 张定宝 陈应辉[1] CHEN Kunlun;ZHANG Dingbao;CHEN Yinghui(Pingchang County People′s Hospital,Bazhong,Sichuan,China 636400)

机构地区：[1]四川省平昌县人民医院,四川巴中636400

出　　处：《中国药业》2024年第15期102-105,共4页China Pharmaceuticals

基　　金：四川省医学会2018年医学科研课题计划项目[S18042]。

摘　　要：目的 探讨通心络胶囊联合瑞舒伐他汀治疗冠状动脉粥样硬化性心脏病(简称冠心病)的临床疗效,以及对患者Toll样受体4(TLR-4)m NRA、核因子κB(NF-κB)m NRA的影响。方法 选取医院2021年5月至2023年5月收治的冠心病患者100例,按随机数字表法分为观察组和对照组,各50例。两组患者均予瑞舒伐他汀治疗,观察组患者加用通心络胶囊治疗。两组患者均治疗28 d。结果 观察组总有效率为96.00%,显著高于对照组的72.00%(P <0.05);治疗后,两组患者的肌钙蛋白T(CTn T)、肌酸激酶同工酶(CK-MB)、总胆固醇(TC)、甘油三酯(TG)水平及左心室舒张末期内径(LVEDd)、左心室收缩末期内径(LVESd)均显著降低,左室射血分数(LVEF)显著升高,且观察组上述指标改善优于对照组(P <0.05);治疗后,两组患者的TLR-4 m NRA及NF-κBm NRA表达水平均显著降低,且观察组显著低于对照组(P <0.05);观察组和对照组不良反应发生率相当(10.00%比6.00%,P> 0.05)。结论 通心络胶囊联合瑞舒伐他汀治疗冠心病疗效好,能够调节TLR-4 m NRA和NF-κBm NRA表达水平,改善血清学、心功能指标,且安全性较高。Objective To investigate the clinical efficacy of Tongxinluo Capsules combined with rosuvastatin in the treatment ofcoronary heart disease(CHD),and the effect on toll-like receptor 4(TLR-4) m NRA and nuclear factor-κB(NF-κB)m NRA in patients with CHD.Methods A total of 100 patients with CHD admitted to the hospital from May 2021 to May 2023were selected and randomly divided into the observation group and the control group by the random number table method,with 50 casesin each group.The patients in the two groups were treated with rosuvastatin,on this basis,the patients in the observation groupwere treated with Tongxinluo Capsules.Both groups were treated for 28 d.Results The total effective rate in the observation groupwas 96.00%,which was significantly higher than 72.00% in the control group(P < 0.05).After treatment,the levels of cardiactroponin T(CTn T),creatine kinase isoenzyme(CK-MB),total cholesterol(TC),triglycerides(TG),left ventricular end-diastolicdiameter(LVEDd),and left ventricular end-systolic diameter(LVESd) in the two groups significantly decreased,while the leftventricular ejection fraction(LVEF) in the two groups significantly increased,and the improvement of the above indicators in theobservation group was significantly better than that in the control group(P < 0.05).After treatment,the expression levels ofTLR-4 m NRA and NF-κB m NRA in the two groups significantly decreased,and those in the observation group weresignificantly lower than those in the control group(P < 0.05).The incidence of adverse reactions was comparable between theobservation group and the control group(10.00% vs.6.00%,P > 0.05).Conclusion Tongxinluo Capsules combined withrosuvastatin have good efficacy and safety in the treatment of CHD,which can regulate the expression levels of TLR-4 m NRAand NF-κB m NRA,and improve serological and cardiac function indexes.

关 键 词：冠状动脉粥样硬化性心脏病 通心络胶囊 瑞舒伐他汀 疗效 TOLL样受体4 核因子ΚB 

分 类 号：R285.6[医药卫生—中药学] R2[医药卫生—中医学]